BDR Pharma brings advanced cancer drug to India at affordable rates

The drug has been tested efficiently in mass Phase-3 trials

55
Medicine
Picture: Pixabay

Last Updated on October 2, 2021 by The Health Master

Advanced cancer drug to India at affordable rates

In its vision to make globally available high-cost medicines accessible to the Indian masses at affordable prices, BDR Pharma has always been a key player. Its latest breakthrough has come with the introduction of Cabozanib molecule named Cabozantinib, a new TKI inhibitor, which has finally been green-lit in the country for cancer treatment.

For the uninitiated, Cabozanib is an oral drug, consumed in the form of tablets, which has vastly helped in the efficacy of treatment for Medullary Thyroid Cancer, Renal Cell Carcinoma and Hepatocellular Carcinoma in particular.

In a highly interactive and educational panel discussion hosted by BDR Pharma and ETHealthworld.com, leading professionals from the healthcare industry have listed out the key benefits of Cabozanib, how it helps fight the different types of cancer and why it is a better substitute to the existing immunotherapy drugs.

The panelists—Dr. Rajat Saha, Senior Consultant Medical Oncology, Max Super Speciality Hospital, Delhi and Dr. K. Pavithran, Clinical Professor and Head Department: Medical Oncology, Amrita Hospitals, Kochi exchange keynotes regarding the advanced drug and its efficacies in cancer treatment.

Speaking to moderator Kanishk Gaur, Founder, India Future Foundation, they have also explained the risk factors to the three types of cancers, what the treatment process for each entails (with respect to the introduction of Cabozanib) and how to adopt lifestyles that can prevent from the disease.

Medullary Thyroid Cancer in India

Thyroid cancers, which rank 18th or 19th in the list of prevalence and incidence of cancers in India, are usually uncommon amidst the general population, with Medullary Thyroid Cancer constituting about 5% of all the different thyroid cancers.

Usually, most of the cases are caused due to genetics, while others are sporadic. Even within the sporadic cases, about 50% of them are due to genetic mutations.

“For the purpose of diagnosis and treatment, we need people to undergo genetic testing. This happens in two parts, one to see if the disease is hereditary, and second to figure out how to go about treatment,” says Dr. Pavithran.

Using Cabozanib to Treat Medullary Thyroid Cancer

The treatment process for this type of cancer depends on the stage of the disease and the physical fitness of the patient. In the early stages, surgery is a curative option.

For later-stage patients, treatment usually comes in the form of radiotherapy and systemic therapy. In the second case, the treatment is meted out through the usage of advanced drugs, which thanks to BDR Pharma’s initiative, is expected to make positive breakthroughs.

The Cabozanib drug comes in the form of tablets that are to be taken orally. A patient would generally have to intake about 140 milligrams a day, but the dosage can be changed according to the response of the patient. Naturally, the pills would have to be taken for a long time.

“The drug has been tested efficiently in mass Phase-3 trials and has indicated an overall promising survival rate when consumed by patients,” says Dr. Saha.

Renal Cell Carcinoma

Kidney cancers rank about 20th on the list of all types of cancers according to incidence and prevalence, in India. Its key causes are smoking, genetic syndromes, and long-standing uncontrolled hypertension.

Maharashtra FDA issues stop sale order to 246 pharmacies

Companies charging these ceiling price not under its purview: NPPA clarifies

FDA to check food licenses of all street vendors

Lupin launches Droxidopa capsules

Pfizer to soon submit data on C-19 vaccine for kids aged…

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner